CNSYNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

PLUS THERAPEUTICS, Inc

Cerenome, Inc. is a U.S.-based CNS oncology company developing precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its platform combines the CNSide laboratory-developed diagnostic, rhenium (186Re) obisbemeda, 188RNL-BAM, proprietary data, and related manufacturing capabilities through subsidiaries and external partners.

Kysy yhtiöstä
Liikevaihto5,2milj. USD
−10,5 %v/v
Liikevoitto (EBIT)−15,3milj. USD
−4,1 %v/v
EBIT-marginaali−293,5%
−41,1 %-yks.v/v
Nettotulos−22,4milj. USD
−72,5 %v/v
Vapaa kassavirta−20,8milj. USD
−94,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−20−10010milj. USD2020: EBIT −9,6 milj. USD20202021: EBIT −12 milj. USD20212022: EBIT −20 milj. USD20222023: EBIT −13 milj. USD20232024: 5,8 milj. USD2024: EBIT −15 milj. USD20242025: 5,2 milj. USD2025: EBIT −15 milj. USD20255,2−15
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: PLUS THERAPEUTICS, Inc

Liiketoiminta

Osuus liikevaihdosta
Targeted CNS radiotherapeutics70 %

Radiopharmaceutical candidates designed for localized treatment of CNS cancers.

CNS diagnostics10 %

CNSide® tests intended to identify tumor cells in cerebrospinal fluid.

Solid-tumor radiotherapeutics15 %

188RNL-BAM is being developed for liver and other solid-organ cancers.

Manufacturing and platform capabilities5 %

Proprietary production workflows, microfluidic chips, reagents, and analytical capabilities support development programs.

Asiakkaat

Cerenome’s commercial and development customers include hospitals, cancer centers, neuro-oncology practices, clinical laboratories, and research institutions that may use CNSide or participate in clinical programs. Future radiotherapeutic customers are expected to include healthcare providers and treatment centers seeking localized options for glioblastoma, leptomeningeal metastases, pediatric brain cancers, and other solid tumors. Payers and distribution or manufacturing partners also influence adoption through reimbursement, supply, and commercialization requirements.

Hospitals and cancer centers

Potential users of CNSide and localized radiotherapeutic procedures for complex CNS cancers.

Neuro-oncology practices

Use diagnostic information and targeted treatment options in CNS cancer management.

Clinical laboratories

Perform or support CNSide testing and related sample-processing workflows.

Academic and clinical research institutions

Participate in trials and generate clinical evidence for product candidates.

Pharmaceutical and manufacturing partners

Provide development, manufacturing, supply, or commercialization capabilities.

Strategia

Cerenome is building an integrated CNS oncology model that links precision diagnostics, targeted radiotherapeutics, and proprietary clinical data. Near-term priorities include commercializing CNSide, advancing rhenium (186Re) obisbemeda and 188RNL-BAM through clinical development, and expanding standardized production capacity. The company also uses contract research and manufacturing partners to extend capabilities while building internal analytical, ERP, and operational infrastructure.

CNSide commercial rolloutLyhyt aikaväli

Diagnostic revenue can establish a commercial entry point before therapeutic approvals.

Advance targeted radiotherapeuticsKeskipitkä aikaväli

Clinical validation and regulatory progress are required to convert candidates into products.

Build scalable operating infrastructureKeskipitkä aikaväli

Standardized manufacturing and planning support higher clinical and commercial volumes.

Integrate the CNS oncology platformPitkä aikaväli

Combining diagnostics and therapeutics may improve disease characterization and treatment positioning.

Maantiede

Cerenome is headquartered and principally operates in the United States, with operations and facility expansion centered in Houston, Texas. Its clinical, regulatory, manufacturing, and commercial activities are U.S.-focused in the available reports, while future product candidates may require approvals and commercialization capabilities in additional jurisdictions. No country-level revenue percentages are disclosed in the provided excerpts.

Riskit

Cerenome remains dependent on successful clinical development, regulatory approval, reimbursement, and commercialization of investigational products. Its development model also relies heavily on CROs, hospitals, clinical investigators, and CMOs, creating execution, supply, quality, and data-integrity exposure. Continuing losses and operating cash use increase financing and going-concern risk while competition may reduce future market access or pricing.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory approval failure2Financing and going-concern risk3Third-party manufacturing dependence4Third-party clinical execution5Reimbursement and market adoption6Competitive displacement7
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea

    Negative efficacy, safety, or manufacturing data could end programs before approval.

    Kohdistuu: Rhenium (186Re) obisbemeda and 188RNL-BAM

  2. Regulatory approval failureVaikutus: KriittinenTodennäköisyys: Korkea

    Radiopharmaceuticals and diagnostics face extensive, costly, and unpredictable requirements.

    Kohdistuu: FDA and other health authorities

  3. Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea

    Operating cash use and continuing losses may require additional capital before products generate material revenue.

    Kohdistuu: Corporate liquidity and development funding

  4. Third-party manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    CMO capacity, compliance, quality, or supply interruptions could delay trials or launch.

    KohdistuuDrug substanceDrug productStorageDistribution
  5. Third-party clinical executionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    CRO, hospital, or investigator failures could delay trials or compromise data integrity.

    Kohdistuu: Clinical trial operations

  6. Reimbursement and market adoptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Inadequate coverage, pricing, or treatment convenience could restrict demand.

    Kohdistuu: Future CNSide and radiotherapeutic commercialization

  7. Competitive displacementVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Other biotechnology, pharmaceutical, device, and diagnostic companies may deliver safer or more effective alternatives.

    Kohdistuu: CNS oncology and laboratory diagnostics

Kysy Clarifolta: PLUS THERAPEUTICS, Inc

Kirjanpito

Harkinnanvaraiset erät
Diagnostic revenue recognition

Commercial CNSide billing requires revenue to be recognized as testing obligations are fulfilled.

Vaikutus: Timing and classification of emerging diagnostic revenue

Grants and awards

Estimates related to grants and awards affect recognized assets, liabilities, and expenses.

Vaikutus: Potential changes to operating results and balance-sheet values

Indefinite-lived intangible assets

Impairment judgments can materially change asset carrying values and reported losses.

Vaikutus: Non-cash impairment expense

Share-based compensation

Equity awards require valuation assumptions and increase reported operating expense.

Vaikutus: Expense recognition and dilution analysis

Warrant fair value

Warrant valuation depends on market and other assumptions and may change between periods.

Vaikutus: Non-cash gains or losses and liability balances

Going-concern assessment

Continuing losses and operating cash use require evaluation of funding and liability settlement assumptions.

Vaikutus: Financial statement disclosure and investor risk assessment

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

CNS Pharmaceuticals, Inc.

CNSP · Pharmaceutical Preparations

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Praxis Precision Medicines, Inc.

PRAX · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026